Written and maintained by CASRAI Editorial Board
Published
On this page
ICH Q5A(R2), “Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin”, is the International Council for Harmonisation guideline that describes how manufacturers evaluate the viral safety of biological products, including cell line testing, testing of unprocessed bulk, and virus clearance studies, and what data to submit in a marketing application. The revised text (R2) reached ICH Step 4 on 1 November 2023, and the US FDA published it as final guidance in January 2024. This guide maps the document section by section, explains how its virus clearance study expectations work, and shows the reduction-factor arithmetic with a clearly labelled illustrative example. It is a regulatory-science explainer and is not advice for any specific product or filing.
What is ICH Q5A?
ICH Q5A is the quality guideline on the viral safety of biotechnology products made from cell lines of human or animal origin. As described in the Step 4 document, it covers the evaluation of viral safety, including viral clearance and testing, and the data to include in marketing applications. The original Q5A reached Step 4 on 5 July 1997, an editorial revision (R1) followed on 23 September 1999, and the full revision Q5A(R2) was endorsed at Step 2 on 29 September 2022 and adopted at Step 4 on 1 November 2023.
The FDA’s guidance page (checked 2026-11-19) lists the R2 text as final guidance from January 2024, announced in the Federal Register on 11 January 2024 (notice 2024-00407, docket FDA-2022-D-2512), issued by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. It replaces the November 2022 draft and updates the original Q5A that the agency issued in September 1998. ICH guidelines are harmonised recommendations, so the version a sponsor follows in a given region is the one that regional authority has implemented; the FDA dates above apply to the United States only.
Who runs it and where it sits
ICH Q5A belongs to the Quality (Q) series of ICH guidelines, alongside documents such as the ICH Q7 GMP guideline for active pharmaceutical ingredients, ICH Q9 quality risk management and ICH Q10 pharmaceutical quality system. Q5A covers the viral-safety slice of biologics quality; the data it describes end up in the quality part of a submission, which is discussed in the eCTD Module 3 quality guide.
What does ICH Q5A(R2) cover? Scope and exclusions
As described in section 1 of the Step 4 document, the guideline applies to biotherapeutics and biological products derived from cell lines of human or animal origin, including mammalian, avian and insect cells. The text names cytokines, monoclonal antibodies and recombinant subunit vaccines as examples. R2 also brings certain engineered viral vectors and vector-derived products, for example adeno-associated virus (AAV) and virus-like particles, within scope where they are amenable to viral clearance without a negative effect on the product; those expectations are collected in Annex 6.
Three areas are outside the guideline. Prions and transmissible spongiform encephalopathy agents are excluded, as are inactivated viral vaccines and live attenuated vaccines containing self-replicating agents. Cell therapies are also out of scope, although the text says its principles may be used for biological starting and raw materials. For a worked example of a product class squarely inside the scope, see how monoclonal antibodies are produced in Chinese hamster ovary cells and other mammalian cell culture systems.
How the document is organised: a section map
The Step 4 PDF runs to 52 pages. Its main sections are: 1 Introduction; 2 Potential sources of virus contamination; 3 Cell line qualification (3.1 cell banks, 3.2 testing assays, 3.3 acceptability); 4 Testing of unprocessed bulk; 5 Rationale and action plan for viral testing and clearance evaluation; 6 Evaluation and characterisation of viral clearance procedures; 7 Continuous manufacturing; 8 Summary; and 9 Glossary. Six annexes follow: virus selection, statistics, calculation of the reduction factor, particles per dose, examples of prior knowledge, and viral vectors. The data table below the article lists each section with its topic so you can find the passage you need.
What testing does Q5A(R2) describe, stage by stage?
The guideline layers testing across the cell banks and the production harvest. The table summarises the stages as written in sections 3 and 4 of the Step 4 document.
| Stage | What section 3 or 4 describes |
|---|---|
| Master cell bank (MCB) | Extensive screening for viral contamination using broad and specific assays listed in the guideline’s Table 1; next-generation sequencing (NGS) is encouraged. |
| Working cell bank (WCB) | Tested for viral contamination. |
| Cells at the limit of in vitro cell age (LIVCA) | Tested once. |
| Unprocessed bulk (each harvest) | Adventitious virus testing routinely on each unprocessed bulk. Indicator cultures are observed for 28 days with at least one sub-passage at 2 weeks; the period may be reduced to 14 days with justification based on a risk assessment. Nucleic acid tests or targeted NGS (for example for minute virus of mice) can be used. |
Assays and the move toward NGS
Section 3.2 lists the assay families: retrovirus assays, in vitro infectivity assays, in vivo assays, tests for specific viruses, and molecular methods including nucleic acid tests and NGS (section 3.2.5.2). Under R2, non-targeted NGS with broad detection capability can replace in vivo tests without a head-to-head comparison, and it can supplement or replace in vitro cell culture assays. The text also states that the use of hybridoma ascites is no longer encouraged, with NGS taking the place of the in vivo assay. If an unprocessed bulk test detects an adventitious virus, the harvest should not be used unless that use is justified, and the root cause should be investigated.
What are the guidelines for conducting virus clearance studies?
Virus clearance studies are described in section 6 of ICH Q5A(R2) and its annexes: a virus is deliberately added (spiked) to a process intermediate, the process step is run at small scale, and the virus titre is measured before and after to quantify how much infectious virus the step removes or inactivates. Section 6.2.3 specifies that virus is added to the intermediate at each step being tested, titres are determined before and after the step, and enough replicates are run to support the conclusion.
Choosing the viruses
Section 6.1 and Annex 1 cover virus selection. Annex 1 gives example model viruses, such as SV40 or an animal parvovirus, parainfluenza, influenza or Sindbis virus, and herpes simplex virus 1 or pseudorabies virus, and states these are examples only and their use is not mandatory. For cell substrates that carry retroviral-like particles, the text points to murine retroviruses.
How much clearance counts?
Section 6.3 sets out the interpretation benchmarks. The guideline recommends two distinct viral clearance steps that complement each other, one of which should clear non-enveloped virus effectively. An effective clearance step generally gives a reproducible reduction in virus load of about 4 log10 or more, shown by at least two independent studies. The table below turns that language into a quick reference.
| Reduction at a step | How section 6.3 treats it |
|---|---|
| About 4 log10 or more, reproducible, at least two independent studies | Generally regarded as an effective clearance step. |
| 1 to 3 log10 | Contributes to the overall clearance. |
| Less than 1 log10 | Negligible; ignored unless justified. |
The overall reduction factor is the sum of the individual factors, and the text expects the whole process to eliminate substantially more virus than the amount present in a single-dose equivalent of unprocessed bulk. Annex 4 of the guideline covers the calculation of particles per dose.
Worked example: calculating a reduction factor (illustrative only)
Annex 3 defines the reduction factor Ri as the log10 of the ratio of total virus before the step to total virus after the step, where total virus is volume multiplied by titre. The numbers below are invented to show the arithmetic and do not describe any real product, process or study.
- Before the step: 100 mL at 107 infectious units per mL gives 109 infectious units in total.
- After the step: 120 mL at 103 infectious units per mL gives 1.2 × 105 infectious units in total.
- Ri = log10(109 / 1.2 × 105) = log10(8,333) ≈ 3.9.
- A second, mechanistically different step with Ri ≈ 4.5 would give an overall factor of about 8.4 log10 (the factors are added). Per Annex 3, an individual factor used in the overall calculation should be greater than 1.
The example shows why the guideline works with volumes and not only concentrations: a step that dilutes the material can look better on titre alone than it does on total virus.
Prior knowledge and platform data
Section 6.6 allows data from other products to be applied to the same type of step when the process step is well understood and the representativeness of the earlier data is justified, considering the mechanism, the process parameters, the virus-product interaction and the composition of the intermediate. A conservative claim is advised. Without that justification, product-specific studies are needed. Annex 5 gives examples of prior-knowledge steps: solvent/detergent or detergent inactivation, low pH inactivation, and virus filtration. Filtration steps such as tangential flow filtration belong to ordinary downstream processing but are distinct from the dedicated virus filtration step Annex 5 describes. Section 6.7 asks for re-evaluation of viral clearance when a significant process change is made.
How does R2 handle continuous manufacturing and viral vectors?
Section 7 addresses continuous manufacturing. It expects the sampling strategy to be justified, and the final release to document the absence of viral contamination for the harvest period. Annex 6 covers engineered viral vectors and vector-derived products such as AAV and virus-like particles, within the limits set in section 1. For the product-side context, see the guide to viral vector vaccines.
Compliance steps: how a sponsor works through the guideline
The guideline is a risk-based action plan, set out in section 5 (Table 4 describes Cases A to F). Read in order, the document implies the following workflow; the order is an editorial summary of the sections, not a prescribed checklist.
- Identify the sources of contamination for the cell substrate and process (section 2).
- Qualify the cell line: master cell bank, working cell bank and LIVCA testing with the assay set justified for the cell type (section 3).
- Test each unprocessed bulk harvest with the justified assay set (section 4).
- Use the section 5 rationale to decide how testing and clearance evaluation fit together for the product.
- Design and run the clearance studies, choosing viruses and replicates and interpreting reduction factors (section 6).
- Re-evaluate when the process changes significantly (section 6.7), and address continuous manufacturing separately where applicable (section 7).
- Summarise the viral safety evaluation for the submission (section 8).
These activities sit inside a wider quality system. See current good manufacturing practice for the general framework.
Common mistakes when reading Q5A(R2)
- Treating the 4 log10 figure as a pass mark for the whole process. Section 6.3 describes it as a benchmark for an effective individual step, and the overall factor is the sum across steps compared against the virus load in a single-dose equivalent of unprocessed bulk.
- Counting steps with under 1 log10 reduction. The text says these are negligible and ignored unless justified.
- Assuming the model viruses are mandatory. Annex 1 gives examples only.
- Carrying clearance data across products without justification. Section 6.6 requires the representativeness of the earlier data to be justified and conservative claims are advised.
- Ignoring process changes. Section 6.7 requires re-evaluation after significant change.
- Applying the guideline to out-of-scope products. Cell therapies, prions and inactivated or live attenuated vaccines containing self-replicating agents are outside section 1.
Related guidelines and pages
| Topic | Relevance to Q5A |
|---|---|
| ICH Q7 | GMP guidance for active pharmaceutical ingredients. |
| ICH Q9 | Quality risk management. |
| ICH Q10 | Pharmaceutical quality system. |
| eCTD Module 3 | Where quality data from the evaluation are presented in a submission. |
Frequently asked questions
What is ICH Q5A?
It is the ICH quality guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, covering testing, virus clearance and the data to submit. The current revision, Q5A(R2), was adopted at Step 4 on 1 November 2023.
What are the guidelines for conducting virus clearance studies?
Section 6 and Annexes 1 to 5 describe them: spike a virus into each process intermediate being tested, measure titres before and after, run enough replicates, and interpret reduction factors, with about 4 log10 or more per effective step shown by at least two independent studies and an overall factor that is the sum of the steps.
Does Q5A(R2) apply to viral vectors such as AAV?
Certain engineered viral vectors and vector-derived products, for example AAV and virus-like particles, are in scope when they are amenable to viral clearance without a negative effect on the product. Annex 6 covers them.
Can next-generation sequencing replace the in vivo assay?
Section 3.2.5.2 says non-targeted NGS with broad detection can replace in vivo tests without a head-to-head comparison, and it may supplement or replace in vitro cell culture assays.
How long are indicator cultures observed for unprocessed bulk?
Section 4 describes 28 days with at least one sub-passage at 2 weeks, reducible to 14 days when justified by a risk assessment.
Sources
- ICH, Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, Step 4, 1 November 2023 (checked 2026-11-19).
- US FDA, Q5A(R2) guidance document (PDF) (checked 2026-11-19).
- Federal Register, Notice of availability, 11 January 2024 (2024-00407) (checked 2026-11-19).
- US FDA, Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin, guidance page (checked 2026-11-19).
Data: ICH Q5A(R2) section and annex map
Section-by-section map of the ICH Q5A(R2) Step 4 guideline (1 November 2023) compiled from the full guideline text, listing each section or annex, its topic and the key content it holds.
Period covered: 2023.
| Section | Topic | Key content |
|---|---|---|
| 1 | Introduction and scope | Biotherapeutics from human or animal cell lines; viral vectors in scope via Annex 6; prions, inactivated and live attenuated self-replicating vaccines excluded |
| 2 | Potential sources of virus contamination | Sources of virus contamination |
| 3 | Cell line qualification | 3.1 cell banks (MCB, WCB, LIVCA); 3.2 assays including retrovirus, in vitro, in vivo, specific virus and molecular methods (NAT, NGS); 3.3 acceptability |
| 4 | Testing of unprocessed bulk | Routine adventitious virus testing on each bulk; indicator cultures 28 days with sub-passage at 2 weeks, 14 days if justified |
| 5 | Rationale and action plan | Rationale and action plan; Table 4 sets out Cases A to F |
| 6 | Evaluation of viral clearance | 6.1 virus choice; 6.2 design; 6.3 interpretation (about 4 log10 per effective step); 6.4 limitations; 6.5 statistics; 6.6 prior knowledge; 6.7 re-evaluation |
| 7 | Continuous manufacturing | Sampling strategy justified; final release documents absence of viral contamination for the harvest period |
| 8 | Summary | Summary of the guideline |
| 9 | Glossary | Glossary |
| Annex 1 | Choice of viruses for clearance studies | Example model viruses; use not mandatory |
| Annex 2 | Statistical considerations | Statistical considerations |
| Annex 3 | Calculation of reduction factors | Ri = log10 of (volume x titre before) / (volume x titre after); individual factor used should be greater than 1 |
| Annex 4 | Calculation of particles per dose | Calculation of particles per dose |
| Annex 5 | Prior knowledge examples | Solvent/detergent or detergent inactivation, low pH, virus filtration |
| Annex 6 | Viral vectors | AAV and virus-like particles within defined limits |
Sources
- ICH Q5A(R2) Step 4 guideline (accessed 2026-11-19)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







